Agentix Corp
OTC:AGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Agentix Corp
Other Equity
Agentix Corp
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Agentix Corp
OTC:AGTX
|
Other Equity
$50.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Equity
-$14.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$1.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Equity
-$8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Equity
-$4.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Equity
-$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
5%
|
|
Agentix Corp
Glance View
Agentix Corp.is a biotechnology company. The company is headquartered in Dana Point, California. The company went IPO on 2015-08-05. The firm is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein-coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. The company has licensed patented, synthetically derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. The firm is also engaged in clinical trials of its product line. Its wholly owned subsidiary is GSL Healthcare, Inc.
See Also
What is Agentix Corp's Other Equity?
Other Equity
50.2k
USD
Based on the financial report for Dec 31, 2025, Agentix Corp's Other Equity amounts to 50.2k USD.
What is Agentix Corp's Other Equity growth rate?
Other Equity CAGR 1Y
22%
Over the last year, the Other Equity growth was 22%.
